Arrowhead Research reported $64.2M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Anika Therapeutics USD -2.69M 4.73M Mar/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Incyte USD 414.5M 92.42M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Ligand Pharmaceuticals USD 20.9M 61.44M Jun/2025
Merck USD 8.39B 1.97B Sep/2025
Moderna USD -790M 582M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Novartis USD 5.88B 290M Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
TG Therapeutics USD 37.7M 25.41M Jun/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025
Xencor USD -30.52M 6.39M Jun/2025